Adjuvance Technologies
Adjuvance Technologies is a privately held biopharmaceutical company founded in 2009 and headquartered in Lincoln, Nebraska, with 11–50 employees. It is led by a CEO, co-founder/CBO, and CSO, and has raised capital from Morningside and the Nebraska Angel Network.
- Company typePrivate
- Founded2009
- HeadquartersLincoln, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Adjuvance Technologies firmographics
Firmographics- Name
- Adjuvance Technologies
- Website
- https://adjuvancetechnologies.com
- Company type
- Private
- Founded year
- 2009
- Headcount range
- 11–50 employees
- Short description
- Adjuvance Technologies is a privately held biopharmaceutical company founded in 2009 and headquartered in Lincoln, Nebraska, with 11–50 employees. It is led by a CEO, co-founder/CBO, and CSO, and has raised capital from Morningside and the Nebraska Angel Network.
- Ownership category
- akta.pro rank
Adjuvance Technologies industry classification
Industry- Product category
- Biopharmaceutical adjuvants
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Adjuvants & Formulation Systems (HLAIAEAI)
- akta.pro secondary industry
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)
Keywords
Where Adjuvance Technologies is headquartered
LocationHeadquarters
- HQ city
- Lincoln
- HQ country
- United States
- HQ region
- North America
Markets served
Adjuvance Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Adjuvance Technologies product offering
Product offeringCore offering
Adjuvance Technologies is a biopharmaceutical company that develops vaccine adjuvants — specialized compounds designed to enhance the immune response when co-administered with vaccine antigens. The company focuses on proprietary adjuvant chemistry intended for use by vaccine developers and other biopharmaceutical manufacturers. Its commercial scope is research-and-development-driven, supplying enabling technology rather than finished vaccines.
Differentiator
Problem solved
Functional benefit
Products and services
- Proprietary vaccine adjuvant technology platform A proprietary vaccine adjuvant platform offering specialized immunological-enhancing compounds intended for incorporation into vaccine products. The platform is targeted at vaccine developers and biopharmaceutical manufacturers that need enabling adjuvant technology to improve immune response in their vaccine candidates.
Companies that use Adjuvance Technologies
Customer profileIdeal customer profiles2 records
Adjuvance Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Adjuvance Technologies competitors and assessment
Company assessmentDirect peers
- Dynavax Technologies: Dynavax is a direct peer: it commercializes the CpG 1018 adjuvant used in HEPLISAV-B and licensed to vaccine developers globally. Adjuvance Technologies operates in the same vaccine-adjuvant-development niche with a similar independent-platform business model.
Broad incumbents
- GSK (Vaccines Business): GSK owns the industry-leading AS01 and AS03 adjuvant systems used in Shingrix and pandemic influenza vaccines. As a broad incumbent it competes with independent adjuvant specialists like Adjuvance for adjuvant licensing partnerships with vaccine developers.
- Novavax: Novavax commercializes the Matrix-M saponin-based adjuvant paired with its nanoparticle vaccines. It is comparable as a vaccine developer whose competitive moat depends in part on proprietary adjuvant IP similar in role to what Adjuvance is developing.
- CSL Seqirus: CSL Seqirus uses the MF59 squalene emulsion adjuvant across its influenza vaccine portfolio. It is comparable as a large vaccine incumbent whose adjuvant platform competes for inclusion in licensed vaccine products.
- Sanofi Pasteur: Sanofi Pasteur is a major vaccine developer with internal adjuvant development capabilities. It overlaps with Adjuvance as a potential partner or acquirer for proprietary adjuvant technologies needed in its vaccine pipeline.
- Merck & Co. (Vaccines): Merck's vaccine division uses proprietary adjuvant systems in products like Gardasil. Comparable to Adjuvance as a large pharmaceutical incumbent with internal adjuvant IP that competes in the same downstream licensing and partnership markets.
Emerging players
- Vaxine Pty Ltd: Vaxine is an Australian adjuvant-focused biotech advancing its Advax/squalene-based platform in partnerships. It is comparable to Adjuvance as a small independent adjuvant specialist with a similar R&D-driven, licensing-oriented business model.
- BioNTech: BioNTech is an mRNA vaccine developer that incorporates lipid nanoparticle and adjuvant strategies for immune potentiation. It is comparable to Adjuvance as a vaccine developer dependent on effective adjuvants, either developed in-house or licensed, for its product candidates.
Market position
Customer concentration
Adjuvance Technologies social profiles
Digital presenceAdjuvance Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adjuvance Technologies leadership team
Management profileNumber of profiles
Profiles3 records
Adjuvance Technologies funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adjuvance Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adjuvance Technologies
What does Adjuvance Technologies do?
Adjuvance Technologies is a biopharmaceutical company that develops vaccine adjuvants — specialized compounds designed to enhance the immune response when co-administered with vaccine antigens. The company focuses on proprietary adjuvant chemistry intended for use by vaccine developers and other biopharmaceutical manufacturers. Its commercial scope is research-and-development-driven, supplying enabling technology rather than finished vaccines.
When was Adjuvance Technologies founded?
Adjuvance Technologies was founded in 2009. It employs 11 to 50 people.
Where is Adjuvance Technologies based?
Adjuvance Technologies is headquartered in Lincoln, United States, in the North America region.
Who are Adjuvance Technologies's main competitors?
Dynavax Technologies is listed as a direct peer. Broad incumbents are GSK (Vaccines Business), Novavax, CSL Seqirus, Sanofi Pasteur and Merck & Co. (Vaccines). Emerging players are Vaxine Pty Ltd and BioNTech.
Does Adjuvance Technologies have an API?
No public API is recorded for Adjuvance Technologies.
What industry is Adjuvance Technologies in?
Adjuvance Technologies's product category is Biopharmaceutical adjuvants. Its primary akta.pro industry code is HLAIAEAI, Vaccine Adjuvants & Formulation Systems, with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its SIC code is 2834.